EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review

Iulia-Alexandra Voinea iD, Eugenia Petrova, Nicoleta Dumitru, Andra Cocoloș, Dumitru Ioachim, Andrei Liviu Goldstein, Adina Mariana Ghemigian

Journal of Clinical Medicine · 26.11.2024 · 13 (23) · 7161

DOI: 10.3390/jcm13237161 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.11.2024. Verfasst von Iulia-Alexandra Voinea und 6 weiteren Autor:innen. Beteiligte Einrichtung: PhD Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 0505474 Bucharest, Romania. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, granted via institutional program "Publish not Perish", “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid cancer (TC) remains the most common cancer in endocrinology. Differentiated thyroid cancer (DTC), the most common type of TC, generally has a favorable outlook with conventional treatment, which typically includes surgery along with radioiodine (RAI) therapy and thyroid-stimulating hormone (TSH) suppression through thyroid hormone therapy. However, a small subset of patients (less than 5%) develop resistance to RAI. This resistance occurs due to the loss of Na/I symporter (NIS) activity, which is crucial for iodine absorption in thyroid cells. The decline in NIS activity appears to be due to gene modifications, reconfigurations with irregular stimulation of signaling pathways such as MAPK and PI3K/Akt pathways. These molecular changes lead to a diminished ability of DTC cells to concentrate iodine, which makes RAI therapy ineffective. As a consequence, patients with radioiodine-refractory DTC require alternative treatments. Therapy with tyrosine kinase inhibitors (TKIs) has emerged as the primary treatment option to inhibit proliferation and growth of RAIR-DTC, targeting the pathways responsible for tumor progression. In this article, we analyze molecular processes responsible for RAI resistance and explore both conventional and emerging therapeutic strategies for managing RAIR-DTC, aiming to improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

NISRAIR-DTCdifferentiated thyroid canceriodine therapysignal pathwayssurgerytyrosine kinase inhibitors

Autor:innen und Institutionen

  • PhD Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 0505474 Bucharest, Romania.
  • Department of Endocrinology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Clinical Endocrinology V, C.I. Parhon National Institute of Endocrinology, 011863 Bucharest, Romania.
  • Department of Pathology, C.I. Parhon National Institute of Endocrinology, 011863 Bucharest, Romania.
  • Department of Nuclear Medicine, C.I. Parhon National Institute of Endocrinology, 011863 Bucharest, Romania.

ORCID-Profile: Iulia-Alexandra Voinea

Förderung

  • "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, granted via institutional program "Publish not Perish"
  • “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Zitieren

APA

Voinea, I. A., Petrova, E., Dumitru, N., Cocoloș, A., Ioachim, D., Goldstein, A. L., & Ghemigian, A. M. (2024). Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review. Journal of Clinical Medicine, 13(23), 7161. https://doi.org/10.3390/jcm13237161

Vancouver

Voinea IA, Petrova E, Dumitru N, Cocoloș A, Ioachim D, Goldstein AL, et al. Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review. Journal of Clinical Medicine. 2024;13(23):7161. doi:10.3390/jcm13237161

BibTeX
@article{Voinea2024,
  author = {Voinea, Iulia-Alexandra and Petrova, Eugenia and Dumitru, Nicoleta and Cocoloș, Andra and Ioachim, Dumitru and Goldstein, Andrei Liviu and Ghemigian, Adina Mariana},
  title = {Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {23},
  pages = {7161},
  doi = {10.3390/jcm13237161}
}
Kostenlos starten →